Medicines in Development for Older Americans - Report Overview

Medicines in Development for Older Americans - 2013 Report

Selected Medicines in Development for Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States. COPD is a chronic lung disease characterized by progressive limitations of the airflow in and out of the lungs, and increased shortness of breath as the disease progresses.

Alzheimer’s Disease Clinical Trials

The 108 clinical trials listed here include 65 that have not yet started recruiting patients or are just now seeking volunteers to participate and another 43 that are active, but not recruiting new patients. This information is potentially valuable to patients still seeking possible treatments for Alzheimer’s disease. It provides a new therapeutic option to discuss with physicians.

Learn More About Medicines in Development for Women

America's pharmaceutical research and biotechnology companies are developing 851 medicines for diseases that disproportionately affect American women. The medicines in the pipeline for women (either in clinical trials or awaiting review by the Food and Drug Administration) include:

PhRMA Principles on Conduct of Clinical Trials

Developing new therapies to treat disease and to improve quality of life is a long and complex process. A critical part of that process is clinical research, the study of a pharmaceutical product in humans. Without clinical research studies, no new medicines could be made available to patients.

Conduct of Clinical Trials

Learn More About Medicines in Development for Rare Diseases

Learn More About Medicines in Development for Parkinson's Disease

America’s biopharmaceutical research companies are currently developing 37 medicines to help the estimated 1.5 million Americans living with Parkinson’s Disease, a motor system disorder resulting from the loss of dopamine-producing brain cells. All of the medicines are either in clinical trials or awaiting review by the U.S. Food and Drug Administration.

Learn More About Medicines in Development for Mental Illnesses

America’s biopharmaceutical research companies are developing 187 medicines to help the nearly 60 million American adults now suffering from some form of mental illness—from anxiety to depression and from schizophrenia to addictive disorders, such as dependence on alcohol or drugs. All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration.

Pages

Subscribe to RSS - Innovation